Skip to main content
Loading

Advancing CMC for Autologous Cell Therapies: Building Robust, Scalable Platforms

18 Sep 2025
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
  • Streamlining upstream and downstream workflows to support consistent and scalable autologous production
  • Implementing sensitive, phase-appropriate assays and comparability studies to ensure product quality and potency
  • Regulatory Alignment: Designing CMC frameworks that anticipate regulatory expectations across development stages
Industry Expert
Heike Abeck, Senior Director, BioPartnering & Development Program Lead - Bayer